US3755581036
US3755581036
Gilead Sciences, Inc.
Loading chart...
Elevated Business & Solvency Risk
Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 45/100).
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
6/7 High
6 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.3x).
Beta (Market Relation)
0.33x
DefensiveVolatility (5Y p.a.)
24.8% p.a.
5-Year HorizonMax Drawdown (5Y)
-29.4%
5-Year HorizonSharpe Ratio
0.57
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +24.4% |
| 3 Years | 26.2% | -27.6% | 0.86 | +25.1% |
| 5 Years | 24.8% | -29.4% | 0.57 | +16.7% |
| 10 Years | 25.6% | -36.2% | 0.17 | +6.9% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 223%.
Unprofitable business model: The company is currently generating net losses.
Corporate Governance & ISS Scores
Overall Governance Risk
5 ISS Score: 5 / 10
Audit Risk
9 ISS Score: 9 / 10
Board Risk
5 ISS Score: 5 / 10
Short Ratio
3.45